ENABLE-2 News and media coverage

ENABLE-2 will receive extended funding through 2028

In the Research Bill 2024, the Swedish government is investing SEK 6.5 billion in free research and innovation of the highest quality. As part of this investment, SEK 100 million is allocated to ENABLE-2. The amount will be SEK 25 million annually through 2028.

"The Swedish government's announcement is very positive and encouraging message to research groups in both Sweden and Europe,” states Anders Karlén, Professor of Computer-aided drug design and coordinator of ENABLE-2.

Symposium: Antibiotic Discovery & New Approaches to Infection Treatment

ENABLE-2, UAC and The Swedish Pharmaceutical Society invite to joint symposium: Antibiotic Discovery & New Approaches toInfection Treatment. This meeting is a forum to discuss current efforts to nourish the antibiotic discovery pipeline & to learn about the latest updates from the ENABLE-2 programme.

We will meet 3rd December, 8:30–15:30 at the Uppsala University Main Building, hall IX. Free event with Lunch & Coffee included. Register here no later than 10 November.

ENABLE-2 expands its portfolio with a British programme

ENABLE-2 welcomes a drug development programme led by Professor Christopher Schofield and Dr. Alistair Farley at the Ineos Oxford Institute for antimicrobial research (IOI), based at the University of Oxford.

"We are very happy that ENABLE-2 continues to consolidate its international presence with this promising programme," states Anders Karlén, Coordinator of ENABLE-2 and Professor of Computer-aided drug design at Uppsala University.

Research breakthrough in fight against resistant bacteria

Researchers at Uppsala University have identified a new class of antibiotics with potent activity against the multi-drug resistant bacteria that WHO pinpoints as the most critical to develop novel treatments for.

"That our compound can cure bloodstream infections in mice models indicates great potential," says Anders Karlén, Professor of Computer-aided drug design at the Department of Medicinal chemistry.

Chemistry Journal reporting from ENABLE-2 and the fight against resistent bacteria

The new issue of Swedish magazine Kemisk Tidskrift turns the spotlight on the rising threat posed by bacteria and the researchers leading the search for new weapons to fight antimicrobial resistance.

In the five page centerpiece, Professors Anders Karlén and Diarmaid Hughes talk about the ongoing work at antibiotic platform ENABLE-2.

ENABLE-2 expanding its project portfolio with two new programmes

Antibiotic platform ENABLE-2 welcomes two new programmes: the "Ornicidine" programme, a scientific collaboration between Leiden University (NL) and Queen's University Belfast (GB); and the "BamA Inhibitors" programme, based at Justus Liebig University Giessen and Fraunhofer IME (D).

“We are very happy with the great interest ENABLE-2 is generating in Europe, and we are raising our international presence to another level,” states Coordinator Anders Karlén.

ENABLE-2 funders

ENABLE-2 is supported by the Swedish Research Council, the National Research Programme on Antibiotic Resistance and Sweden's innovation agency Vinnova.